

CURRICULUM VITAE

SHRINATH BARATHAN, M.D.

**Cedars Sinai Medical Towers
Tower Nephrology Medical Group
8635 West 3rd St. Suite # 485-W
Los Angeles, CA 90048
(310) 652 9162
info@towernephrology.com**



PROFESSIONAL EXPERIENCE:

Clinical Chief of Nephrology. 2013–Present. Cedars Sinai Medical Center, Los Angeles.

Assistant Professor of Medicine. 2011–Present. David Geffen School of Medicine, UCLA.

Clinical Instructor. 2004–2011. David Geffen School of Medicine, UCLA.

Attending Staff Physician. 2003–Present. Cedars Sinai Medical Center, Los Angeles.

Preceptor. 2012–Present. School of Nursing. California State University, Los Angeles.

Partner. 2003–Present. Tower Nephrology Medical Group, Los Angeles.

Assistant Medical Director. 2009–Present. Crescent Heights Dialysis Center. Los Angeles.

COMMITTEES AT CEDARS SINAI MEDICAL CENTER:

Department of Medicine Performance Improvement Committee. 2013–Present.

Pharmacy and Therapeutics Committee. 2008–Present.

Joint Dialysis Oversight Committee. 2010–Present.

Best Practices for Continuous Veno-Venous Hemodialysis. 2010–Present.

Cardiac Surgical ICU Innovation Project. 2015–Present.

Vaptan Task Force. 2010–Present.

Code Sepsis Committee - Clinical Team to device protocols for septic patients. 2011-Present.

Electronic Medical Record. CS Link Nephrology Task Force. 2011-Present.

EDUCATION AND TRAINING:

College: BS in Chemistry. Presidency College, Madras University, India. 1983-1986.

Medical School: MD. 1987-1993. National Pirogov Memorial Medical University, Vinnytsya. Ukraine.

Residency: Internal Medicine, 1997-2000. MetroHealth Medical Center, The Rammelkamp Center for Education and Research, MetroHealth Medical Center. Case Western Reserve University, Cleveland, Ohio.

Fellowship: Nephrology, 2000-2003. University Hospitals, MetroHealth Medical Center, VA Medical Center, Cleveland, Ohio. Case Western Reserve University.

AWARDS AND CERTIFICATIONS:

1987 Fully funded scholarship to medical school sponsored by Governments of India and USSR.

1993 Certified Teacher of Russian Language.

2000 Diplomate in Internal Medicine, American Board of Internal Medicine.

2000 ACLS Provider

2000 BLS Provider

2003 Board Certified, Subspecialty Board in Nephrology, American Board of Internal Medicine.

LICENSURES:

California State Medical Board

OTHER SERVICES:

President. 1986-1987. Foreign Students Association. National Pirogov Memorial Medical University, Vinnytsya. Ukraine.

SCIENTIFIC PRESENTATIONS:

Senior Resident Grand Rounds, 2000, "Progression of Chronic Renal Disease", Metro Health Medical Center, Cleveland, OH

Research Days 2000, "Comparison of mRNA kidney expression profiles generated by Serial Analysis of Gene Expression (SAGE) to identify candidate nephropathy genes in C57BL/6-Os/ + Versus ROP-Os/ + mice", Rammelkamp Center for Education and Research, MetroHealth Medical Center, Cleveland OH.

Research Days 2002, "The cell guidance molecule neuropilin-2 is under expressed in podocytes of

sclerosis-prone ROP-Os/+, but not C57Bl/6-Os/+mice', Rammelkamp Center for Education and Research, MetroHealth Medical Center, Cleveland, OH.

Journal Club, 2002, "Treatment of Lupus Nephritis", University Hospital of Cleveland, Cleveland, OH.

Journal Club, 2003. "Major Outcomes in High-Risk Hypertensive Patients Randomized Patients Randomized to ACE Inhibitor or Calcium Channel Blocker vs. Diuretic" The ALLHAT Trial. University Hospitals of Cleveland, Cleveland, OH.

CLINICAL STUDY LOCATION:

Tower Nephrology Medical Group, 8635 W. 3RD ST #485W Los Angeles, CA 90048
Da Vita of Beverly Hills, 50 N. La Cienega blvd. #300 Beverly hills, CA 90211
Da Vita of Crescent Heights, 8151 Beverly blvd Los Angeles, CA 90048

CLINICAL STUDIES:

Sub Investigator	2014	Ferumoxytol for Anemia of CDK Trial (FACT): A Phase IV, open Label, Multicenter Trial, with MRI Substudy, of Repeated Doses Ferumoxytol Compared with Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA) in Chronic Kidney Disease (CKD) Patients on Hemodialysis
Sub- Investigator	2014	A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
	2013	ICH Good Clinical Practice for Clinical Trial Sites (Certificates)
Sub- Investigator	2013	A randomized, Double-blind, Placebo-controlled, Phase 3 Study to assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis.
Sub- Investigator	2013	ZS-003: "A Phase III multicenter, Two-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of ZS (Microporous, Fractionated, Protonated Zirconium Silicate), an Oral Sorbent, in Subjects with Mild to Moderate Hyperkalemia.
Sub- Investigator	2013	Randomized, Double-blind, Parallel-group, Multicenter study to evaluate the efficacy and safety of HX575 Epoetin alfa vs. US licensed Epoetin alfa (Epogen/Procrit) in the treatment of anemia associated with chronic kidney disease.

Sub- Investigator	2013	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily Administration of a Chemokine CCR2/5 Receptor Antagonist (PF-04634817) in Adults With Type 2 Diabetes and Overt Nephropathy Study #B1261007-1137
Sub- Investigator	2012	A phase 2b, Prospective, Double- Blind, Placebo- Controlled, Multicenter to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedence, in Type 2 Diabetic Subjects with Nephropathy
Sub-Investigator	2011	A Three-Period, 58-Week Safety and Efficiency Trial of KRX-0502 (ferric citrate) in Patients with End-Stage Renal Disease (ESRD) on Dialysis
Sub- Investigator	2011	Bardoxolone Methyl Evaluation in patients with chronic kidney disease and type 2 diabetes: The occurrence of renal events (Beacon)
Sub-Investigator	2011	A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 2) Study
Sub-Investigator	2010	A 30-Week, multicenter, randomized, double-blind, parallel-group study of the combination of ABT-335 and Rosuvastatin compared to Rosuvastatin Monotherapy in Dyslipidemic subjects with Stage 3 Chronic Kidney Disease.
Sub-Investigator	2010	Study to evaluate the improved management of iPTH with paracalcitolcentered therapy vs. cinacalcet therapy with low-dose vitamin d in hemodialysis patients with secondary hyperparathyroidism
Sub-Investigator	2009	A Phase 2a, prospective, randomized, double-blind, placebo-controlled multicenter study to evaluate the safety and efficacy of Atrasentan on reducing albuminuria in type 2 diabetic nephropathy subjects who are currently being treated with an renin-angiotensin system inhibitor.
Sub-Investigator	2008	Phase 2, randomized, double-blind, placebo-controlled, parallel group, fixed dose study of AMG 223 in subjects with chronic kidney disease on hemodialysis with hyperphosphatemia.
Sub-Investigator	2007	A Phase III, Randomized, active-controlled, open-label, multi-center study of the safety and efficacy of AF37702 injection for the maintenance treatment of anemia in hemodialysis patients previously treated with epoetin
Sub-Investigator	2007	Outcome trial evaluating the efficacy and safety of Norditropin® on adult patients on chronic hemodialysis
Sub-Investigator	2007	Phase IV, Long-term, Observational Safety Study in End Stage Renal

Disease Subjects treated with lanthanum Carbonate (Fosrenol ®)

Sub-Investigator	2007	A Two-Arm, Randomized, Open-Label, Multicenter Study of Safety and Efficacy of Monthly Injections of RO0503821 versus Epoetin Alfa in Peritoneal Dialysis patients who self inject or receive in-center injections.
Sub-Investigator	2007	Prospective, Open Label, Randomized multicenter study to demonstrate The efficacy and safety of intravenous (IV) RO0503821 for hemoglobin control in patients transitioning from chronic kidney disease. Stage 4 through dialysis.
Sub-Investigator	2007	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease.
Sub-Investigator	2007	A Randomized, Open-Label, multicenter study Epoetin Alfa comparing two extended-dosing regimens, Once-every-Two-Weeks, and Once-Every-Four-Weeks, with the Once-Weekly dosing regimen for maintenance treatment in anemic subjects with chronic kidney disease.
Sub-Investigator	2007	An Open Label Randomized, Paralled-Group, Clinical Endpoint Bioequivalence Study of Generic Iron Sucrose Injection USP Versus Venofer® Iron Sucrose Injection USP in Hemodialysis Patients with Iron Deficiency
Sub-Investigator	2006	A randomised, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist avosentan on time to doubling of serum creatinine, end stage renal disease or death in patients with type 2 diabetes mellitus and diabetic nephropathy.
Sub-Investigator	2006	Evaluation Of Cinacalcet HCl Therapy to Lower cardio Vascular Events.
Sub-Investigator	2006	A Phase III Study of the Safety and Efficacy of Ferumoxytol (compared with oral iron) as an Iron Replacement Therapy in Chronic Kidney Disease Patients not on Dialysis.
Sub-Investigator	2005	An Open-Label, Single-Arm Study to Assess the Safety of Darbepoetin Alfa Manufactured by a Serum Free Bioreactor Technology in Subjects with Chronic Kidney Disease.
Sub-Investigator	2004	Phase IIIb, Multi-Center, Two-Cohort, Randomized Study, with an Open-Label Run-In and a Long-Term Extension Phase, Assessing an Extended Dose Range of Lanthanum Carbonate in End Stage Renal Disease Subjects Receiving Hemodialysis.
Sub-Investigator	2004	Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Efficacy of Staph VAX, a Bivalent <i>Staphylococcus aureus</i> Glycoconjugate Vaccine in Adults on Hemodialysis.

ORIGINAL CONTRIBUTIONS:

Identification of nephropathy candidate genes by comparing sclerosis-prone and sclerosis-resistant mouse strain kidney transcriptomes. El-Meanawy A, Schelling JR, Iyengar SK, Hayden P, Barathan S, Goddard K, Pozuelo F, Elashi E, Nair V, Kretzler M, Sedor JR. *BMC Nephrol*. 2012 Jul 19;13:61. doi: 10.1186/1471-2369-13-61.

Serial analysis of gene expression. El-Meanawy MA, Barathan S, Hayden PS, Iyengar SK, Schelling JR, Sedor JR. *Methods Mol Med*. 2003;86:257-74.

Generation of kidney transcriptomes using serial analysis of gene expression. Schelling JR, El-Meanawy MA, Barathan S, Dodig T, Iyengar SK, Sedor JR. *Exp Nephrol*. 2002;10(2):82-92.

REVIEWS:

M.A. El-Meanawy, J.R. Schelling, S. Barathan, S.K. Iyengar and J.R. Sedor. Serial analysis of gene expression (SAGE). In: *Methods in Molecular Medicine: Renal Disease. Guide to Technical Approaches*. M.S. Goligorsky, ed. The Humana Press, Totowa, NJ, in press 2002.

ABSTRACTS:

Goddard KA, El-Meanawy A, Schelling JR, Elashi E, Barathan S., Konieczkowski M., Kamat S, Koepke S, Covic A, Sedor JR and Iyengar SK. Comparison of mRNA kidney expression profiles generated by serial analysis of gene expression (SAGE) to identify candidate nephropathy genes in C57BL/6Os/+ versus ROP-Os/+mice. *Am J Hum Genet* 67:1456T, 2000.

El-Meanawy, A., J. Schelling, E. Elashi, S. Barathan, M. Konieczkowski, S. Kamaet, A. Koepke,

K. Goddard, A. Covic, S Iyengar and J. Sedor. Comparison of mRNA kidney expression profiles generated by serial analysis of gene expression to identify candidate nephropathy genes in C57BL/6-Os/+ versus ROP-Os/+mice. *J. Am Soc. Nephrol*, 11:617A, 2000.

J.R. Schelling, A. El-Meanawy, E. Elashi, S. Barathan, M. Konieczkowski, S. Kamat, A. koepke, K. Goddard, A. Covic, S.I. Iyanar and J.R. sedor. Comparison of mRNA kidney expression profiles generated by serial analysis of gene expression (SAGE) to identify candidate nephropathy genes in C57BL/6-Os/+ versus ROP-Os/+mice. *Nephrology, Dialysis and Transplantation* 15:A34, 2000.

El-Meanawy, S. Barathen, M. Konieczkoski, E. Elashi A. Covic, T. Dodig, S. Khan, A. Koepke, F. Pozuelo, K. Goddard, S. Iyangar, J.R. Schelling and J.R. Sedor. Gene expression profiles generated by serial analysis of gene expression (SAGE) identify candidate molecular pathways regulating progressive glomerulosclerosis. *Nephrology, Dialysis and Transplantation* 16:A38,2001.

El-Meanawy, M.A., S. Barathan, T. Dodig, E. Elashi, K. Goddard, S. K. Iyengar, J.R. Schelling and John R. Sedor. Kidney transcriptome profiles generated by serial analysis of gene expression identify candidate molecular pathways regulating progressive glomerulosclerosis. *J. Am. Soc. Nephrol*. 12:617A, 2001.

Barathan, S., M. Konieczkowski, A. El-Meanawy*, S. Khan, B. Wang, T. Dodig, S.K. Iyengar, J.R. Schelling and J.R. Sedor. Expression analysis demonstrated the cell guidance signal neuropilin 2b (nrp2) is reduced in sclerosis-prone Rop-Os/+ but not sclerosis-resistant C57-Os/+ mouse kidneys. *J. Am. Soc. Nephrol.* 12:617A, 2001.

P. Hayden, M.A. El-Meanawy, S. Barathan, G. Jarad, M. Srichai, M. Konieczkowski, S. Iyengar, J.R. Schelling, J.R. Sedor. Serial Analysis of Gene expression (SAGE)- Generated Libraries from Kidneys of Sclerosis-Prone and Sclerosis-Resistant Mice Identify a Renal Disease-Associated Replicon. *J. Am. Soc. Nephrol.* 13:118A, 2002.

S. Barathan, S. Iyengar, L. Bruggeman, P. Mundel, M. El-Meanawy, M. Konieczkowski, J. Schelling, J. Sedor. The Cell Guidance Molecule Neuropilin-2 Is Underexpressed in Podocytes of Sclerosis-Prone ROP-Os/+, but Not C57B1/6-Os/+ Mice. *J. Am. Soc. Nephrol.* 13:124A, 2002.

M.B. Srichai, M. Konieczkowski, S. Barathan, S. Khan, P. Mundel, S. Lee, L. Bruggeman, J.R. Schelling, J.R. Sedor. A Novel WT1 Co-Regulator That Shuttles between Nucleus and Plasma Membrane, *J. Am. Soc. Nephrol.* 13:16A, 2001